Resources

71% of Medisafe users improved their adherence after adding a Medisafe Medfriend who is alerted each time a dose is missed.

Here’s what today’s pricing development means for pharma brand marketers, patient support teams, innovation leads, access executives, and procurement leadership—and how Medisafe is uniquely positioned to drive higher adherence, long-term engagement, and ultimately better outcomes for those embarking on complex treatment journeys.

Managing diabetes presents significant challenges both for patients and pharmaceutical companies. Adherence to medication regimens, continuous monitoring, and lifestyle adaptations are critical but often overwhelming.

Multiple Sclerosis (MS) represents a formidable challenge in healthcare, a chronic, often unpredictable disease of the central nervous system that impacts millions worldwide. Its complex nature demands not just cutting-edge therapies but also robust, sustained patient support to navigate the daily realities of living with the condition.

New data reveals a 10% increase in prescription refills for hypertensive patients using Medisafe. Discover how the "on-app" MPR jumped 21.8% for patients previously struggling with adherence.

Download our latest research showing how supporting patient engagement is not only a growing strategic initiative for pharma companies but is proving to be an impactful value driver.

Medication non-adherence causes 125,000 deaths annually in the US. Learn how Medisafe’s ISPOR-presented research proves mobile technology can scale to lower healthcare costs and improve chronic disease outcomes.

Read how Medisafe and Pleio joined forces to help engage patients in their treatment journey through the power of human+digital connection, using a compassionate approach for the digital age to drive better outcomes.

Pharma knows where their pills go, but not what happens next. Explore how digital platforms provide the real-world evidence needed to understand the patient journey beyond the prescription.

Can digital health survive economic uncertainty? Explore how pharma’s investment in patient engagement and EHR connectivity is building a recession-proof future for healthcare.

Medication non-adherence costs $100B annually. Learn how researchers used a standardized six-drug test to separate high-quality adherence apps from the rest of the market.

Medisafe and IQVIA study shows 70% of non-adherent patients became adherent after using the app. Learn how the Medisafe platform impacts refill rates and long-term therapy duration.

Can an app save lives? New clinical research shows Medisafe significantly improves medication adherence for CHD patients. See the data behind the 0.47 MMAS-8 boost.

Medisafe dramatically improved adherence for cohorts of users who historically struggled, because following an HIV regimen correctly is critical to helping people with the disease live full and long lives. The proportion of patients with MPR ≥ 0.80 increased from 82.3% pre-app to 88.6% on-app, a 7.7% relative increase

In just five months, Merck KGaA, Darmstadt, Germany increased adherence rates up to 20% by customizing digital medication programs.